GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
AMICUS THERAPEUTICS (FOLD) [hlAlert]

Rating:
Underperform
FOLD
down 31.52 %

AMICUS THERAPEUTICS (FOLD) downgraded to Underperform with price target $3.50 by Wedbush Morgan

Posted on: Monday,  Oct 5, 2009  9:25 AM ET by Wedbush Morgan

Wedbush Morgan rated Underperform AMICUS THERAPEUTICS (NASDAQ: FOLD) on 10/05/2009. Previously Wedbush Morgan rated Buy AMICUS THERAPEUTICS (NASDAQ: FOLD) on 03/20/2009.,
when the stock price was $8.66. Since then, AMICUS THERAPEUTICS has lost 31.52% as of 10/05/2009's recent price of $5.93.
If you would have followed the previous Wedbush Morgan's recommendation on FOLD, you would have lost 31.52% of your investment in 199 days.

Amicus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The Company?s products in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera (isofagomine tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. The Company completed its Phase II clinical trials of Amigal and are conducting Phase II clinical trials of Plicera and AT2220.

Since 1980, WEDBUSH has used its private equity discipline to invest in under-valued and capital constrained public and private companies that have a significant potential for appreciation. The firm invests with high quality management teams with domain expertise and expects management to retain or make a personally significant equity investment.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/5/2009 9:25 AM Sell
None
5.93 3.50
as of 12/31/2009
1 Week down  -60.05 %
1 Month down  -84.82 %
3 Months down  -36.94 %
1 YTD down  -36.24 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/20/2009 1:25 PM Buy
None
8.66 17.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy